Compass Therapeutics Analyst Ratings
Ladenburg Thalmann Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $5
Leerink Partners Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $5
Compass Therapeutics Strategy Pivot and Outperform Rating Amidst Clinical Setbacks
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $10
Compass Therapeutics (CMPX) Gets a Buy From Stifel Nicolaus
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
Buy Rating Affirmed: Compass Therapeutics' Promising Pipeline and Prudent Financial Outlook
Wedbush Reiterates Outperform on Compass Therapeutics, Maintains $8 Price Target
Compass Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
Buy Rating Affirmed on Compass Therapeutics as Clinical Trials of CTX-009 Show Promise in Biliary Tract Cancer Treatment
Compass Therapeutics Analyst Ratings
Compass Therapeutics Analyst Ratings
Compass Therapeutics: A Buy Rating on Promising Pipeline and Solid Financials
Compass Therapeutics Analyst Ratings
Buy Rating Affirmed for Compass Therapeutics on Strong Financials and Promising Clinical Trials
Compass Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)
Buy Rating on Compass Therapeutics for Breakthrough in Resistant Tumor Treatment
No Data
No Data